A Phase 1-2 Open-Label Dose-Finding Proof of Concept First-in-Human Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors

Brief description of study

If you have an advanced or recurrent solid tumor in one of the following cancer types: breast cancer, castration-resistant prostate cancer, non-small cell lung cancer, epithelial ovarian cancer, endometrial cancer, head and neck squamous cell cancer or cholangiocarcinoma (bile duct cancer) you may qualify to participate in a study evaluating the investigational drug CX-2009. The goal of this phase 1/2 study is to evaluate the possible side effects, safety and tolerability of CX-2009 when given alone in patients with selected advanced or recurrent solid tumors.

Clinical Study Identifier: s17-00690
ClinicalTrials.gov Identifier: NCT03149549
Principal Investigator: Daniel C Cho
Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.